Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 May 2017

Zhang Q Y, Wei X D, Yin Q S, Mi R H, Yuan F F, Chen L

Abstract excerpt

Objective: To analyze the clinical features of acute myeloid leukemia patients with Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation and the therapeutic effect of sorafenib in combination with chemotherapy as first-line therapy for these patients. Methods: Clinical features and therapeutic effect were retrospectively analyzed in 53 AML patients with FLT3-ITD mutation diagnosed in Henan...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sorafenib
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Niacinamide

Share to Phenylurea Compounds

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 28565742
DOI: 10.3760/cma.j.issn.0253-2727.2017.05.012
PMCID: PMC7354192

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia].PMID 28565742Read ↗

[Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].Semantic proximity Read ↗

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].Semantic proximity Read ↗

[Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation].Semantic proximity Read ↗

Prognosis and outcome of patients with acute myeloid leukemia based on FLT3‑ITD mutation with or without additional abnormal cytogeneticsSemantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].Semantic proximity Read ↗

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.Semantic proximity Read ↗

Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.Semantic proximity Read ↗

Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.